GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (XPAR:ALCLS) » Definitions » Research & Development

Cellectis (XPAR:ALCLS) Research & Development : €86.74 Mil (TTM As of Sep. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Cellectis Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Cellectis's Research & Development for the three months ended in Sep. 2024 was €21.47 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 was €86.74 Mil.

Cellectis Research & Development Historical Data

The historical data trend for Cellectis's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Research & Development Chart

Cellectis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 82.84 63.33 104.29 92.04 80.37

Cellectis Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.87 22.89 20.54 21.85 21.47

Cellectis Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €86.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cellectis  (XPAR:ALCLS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Cellectis Research & Development Related Terms

Thank you for viewing the detailed overview of Cellectis's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Cellectis Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (XPAR:ALCLS) » Definitions » Research & Development
Comparable Companies
XPAR:ALACT XPAR:ABNX XPAR:ALGEN XPAR:ALVAL XPAR:GNRO XPAR:PHXM XPAR:ALVIO XPAR:ALDVI XPAR:SIGHT XPAR:MAAT OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
CLLS:USA 0WA2:UK ZVAA:Germany
Address
8, rue de la Croix Jarry, Paris, FRA, 75013
Website
https://www.cellectis.com
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.

Cellectis Headlines

No Headlines